These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 27628221)

  • 61. How B-Type Natriuretic Peptide (BNP) and Body Weight Changes Vary in Heart Failure With Preserved Ejection Fraction Compared With Reduced Ejection Fraction: Secondary Results of the HABIT (HF Assessment With BNP in the Home) Trial.
    Maisel AS; Shah KS; Barnard D; Jaski B; Frivold G; Marais J; Azer M; Miyamoto MI; Lombardo D; Kelsay D; Iqbal N; Taub PR; Kupfer K; Lee E; Clopton P; Zile M; Greenberg B
    J Card Fail; 2016 Apr; 22(4):283-93. PubMed ID: 26433086
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Pharmacotherapy Choice Is Associated with 2-Year Mortality for Patients with Heart Failure and Reduced Ejection Fraction.
    Albert NM; Drzayich Antol DA; DeClue RW; Casebeer AW; Li Y; Stemkowski S; Chang CL
    Adv Ther; 2017 Oct; 34(10):2345-2359. PubMed ID: 29019079
    [TBL] [Abstract][Full Text] [Related]  

  • 63. AT1 receptor blocker added to ACE inhibitor provides benefits at advanced stage of hypertensive diastolic heart failure.
    Yoshida J; Yamamoto K; Mano T; Sakata Y; Nishikawa N; Nishio M; Ohtani T; Miwa T; Hori M; Masuyama T
    Hypertension; 2004 Mar; 43(3):686-91. PubMed ID: 14757777
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Association of pretreatment with angiotensin-converting enzyme inhibitors with improvement in ablation outcome in atrial fibrillation patients with low left ventricular ejection fraction.
    Mohanty S; Mohanty P; Trivedi C; Gianni C; Bai R; Burkhardt JD; Gallinghouse JG; Horton R; Sanchez JE; Hranitzky PM; Al-Ahmad A; Bailey S; Di Biase L; Natale A
    Heart Rhythm; 2015 Sep; 12(9):1963-71. PubMed ID: 26051531
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Ambulatory Blood Pressure Parameters and Heart Failure With Reduced or Preserved Ejection Fraction in Elderly Treated Hypertensive Patients.
    Pierdomenico SD; Pierdomenico AM; Coccina F; Lapenna D; Porreca E
    Am J Hypertens; 2016 Aug; 29(8):1001-7. PubMed ID: 26992413
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
    Ostergren JB
    J Hypertens Suppl; 2006 Mar; 24(1):S3-7. PubMed ID: 16601570
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Comparison of characteristics and outcomes of patients with heart failure preserved ejection fraction versus reduced left ventricular ejection fraction in an urban cohort.
    Quiroz R; Doros G; Shaw P; Liang CS; Gauthier DF; Sam F
    Am J Cardiol; 2014 Feb; 113(4):691-6. PubMed ID: 24484862
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effects of enalapril, candesartan or both on neurohumoral activation and LV volumes and function in patients with heart failure not treated with a beta-blocker.
    White M; Rouleau JL; Afzal R; Floras J; Yusuf S; McKelvie RS
    Ther Adv Cardiovasc Dis; 2009 Apr; 3(2):113-21. PubMed ID: 19299427
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial.
    Cice G; Di Benedetto A; D'Isa S; D'Andrea A; Marcelli D; Gatti E; Calabrò R
    J Am Coll Cardiol; 2010 Nov; 56(21):1701-8. PubMed ID: 21070920
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Beta-blocker therapy and prognosis of heart failure patients with new-onset diabetes mellitus.
    Garcia-Egido A; Andrey JL; Puerto JL; Aranda RM; Pedrosa MJ; López-Sáez JB; Rosety M; Gomez F
    Int J Clin Pract; 2015 May; 69(5):550-9. PubMed ID: 25707623
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effect of olmesartan on oxidative stress in hemodialysis patients.
    Kadowaki D; Anraku M; Tasaki Y; Kitamura K; Wakamatsu S; Tomita K; Gebicki JM; Maruyama T; Otagiri M
    Hypertens Res; 2007 May; 30(5):395-402. PubMed ID: 17587751
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction.
    Gandhi PU; Chow SL; Rector TS; Krum H; Gaggin HK; McMurray JJ; Zile MR; Komajda M; McKelvie RS; Carson PE; Januzzi JL; Anand IS
    J Card Fail; 2017 Jan; 23(1):20-28. PubMed ID: 27317843
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Differential blood pressure reductions by angiotensin receptor blocker plus calcium channel blocker or diuretic in elderly hypertension with or without obesity.
    Kato J; Yokota N; Tamaki N; Kariya S; Kita T; Ayabe T; Eto T; Kitamura K
    J Am Soc Hypertens; 2012; 6(6):393-8. PubMed ID: 23102995
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure.
    Hillege HL; Nitsch D; Pfeffer MA; Swedberg K; McMurray JJ; Yusuf S; Granger CB; Michelson EL; Ostergren J; Cornel JH; de Zeeuw D; Pocock S; van Veldhuisen DJ;
    Circulation; 2006 Feb; 113(5):671-8. PubMed ID: 16461840
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Heart failure: New data do not SUPPORT triple RAAS blockade.
    Danser AH; van den Meiracker AH
    Nat Rev Nephrol; 2015 May; 11(5):260-2. PubMed ID: 25802078
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Implementation of Guideline-Recommended Therapies for Patients With Heart Failure and Reduced Ejection Fraction: A Regional Arab Middle East Experience.
    Zubaid M; Rashed W; Ridha M; Bazargani N; Hamad A; Banna RA; Asaad N; Sulaiman K; Al-Jarallah M; Mulla AA; Baslaib F; AlMahmeed W
    Angiology; 2020 May; 71(5):431-437. PubMed ID: 32066246
    [TBL] [Abstract][Full Text] [Related]  

  • 77. β-Blocker therapy in heart failure with preserved ejection fraction: Importance of dose and duration.
    Yamamoto K
    J Cardiol; 2015 Sep; 66(3):189-94. PubMed ID: 25881728
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Survival and heart failure therapy in chronic dialysis patients with heart failure and reduced left ventricular ejection fraction: an observational retrospective study.
    Derthoo D; Belmans A; Claes K; Bammens B; Ciarka A; Droogné W; Vanhaecke J; Van Cleemput J; Janssens S
    Acta Cardiol; 2013 Feb; 68(1):51-7. PubMed ID: 23457910
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effects of 1-year administration of olmesartan on portal pressure and TGF-beta1 in selected patients with cirrhosis: a randomized controlled trial.
    Hidaka H; Nakazawa T; Shibuya A; Minamino T; Takada J; Tanaka Y; Okuwaki Y; Watanabe M; Koizumi W
    J Gastroenterol; 2011 Nov; 46(11):1316-23. PubMed ID: 21850387
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cardiac overexpression of constitutively active Galpha q causes angiotensin II type1 receptor activation, leading to progressive heart failure and ventricular arrhythmias in transgenic mice.
    Matsushita N; Kashihara T; Shimojo H; Suzuki S; Nakada T; Takeishi Y; Mende U; Taira E; Yamada M; Sanbe A; Hirose M
    PLoS One; 2014; 9(8):e106354. PubMed ID: 25171374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.